NASDAQ : VTRS

Viatris Inc.

$17.59 USD

$0.6 (3.53%)

Volume
7.88M
Average Volume
11.09M
Market Capitalization
$20.48B
P/E Ratio
-66.65
Dividend Yield
2.73%
Price Target
$19.00
Year High
$17.68
Year Low
$8.63
Day High
—
Day Low
—
Payout Ratio
-$1.88
Current Ratio
$1.60
Company Overview

NASDAQ

Scott Andrew Smith

Drug Manufacturers - Specialty & Generic

Healthcare

VTRS

30000

US

USD

https://www.viatris.com

724 514 1800

92556V106

0001792044

Liquidity Metrics

0.98

1.60

1.03

0.26

-1.88

Sales & Valuation

$14.3B

1.41

1.39

11.98

1.48

Profitability

-$3

-$3.51B

-2.04%

-5.60%

-1.97%

-0.80%

P/E Metrics

-66.65

-0.65

-0.65

Analyst Price Target & Rating

$19.00

$22.00

$12.00

Sell

2/5

13 Analysts

-7.42%

Financial Health Scores

1.04

5/9

$4.11B

$36.83B

$22.18B

-$244.4M

Key Metrics (TTM)

$32.33B

2.22

12.60

1.60

-1.97%

0.16%

-1.51%

8.64%

160 days

Company Executives
Name Title
Matthew Joseph Maletta Chief Legal Officer
Andrew Enrietti Chief Administrative & Transformation Officer
Paul Campbell Interim CFO, Chief Accounting Officer & Corporate Controller
Corinne Le Goff Chief Commercial Officer
Peter McCormick Chief Supply Officer
Philippe Martin Chief R&D Officer
Ramkumar V. Rayapureddy Chief Information Officer
Scott Andrew Smith Chief Executive Officer & Director
William Szablewski Head of Investor Relations & Capital Markets
Lara Ramsburg Chief People & Corporate Affairs Officer
Theodora Mistras Executive Officer
Poll Results

No votes yet today — be the first to share your view!

About Viatris Inc. (NASDAQ:VTRS) Stock

Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, cent ... ral nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.

Why Viatris (VTRS) is a Top Value Stock for the Long-Term

2026-07-10 10:41:07

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

VTRS or DHR: Which Is the Better Value Stock Right Now?

2026-07-09 12:40:44

Investors interested in Medical Services stocks are likely familiar with Viatris (VTRS) and Danaher (DHR). But which of these two companies is the best option for those looking for undervalued stocks?

Should Value Investors Buy Viatris (VTRS) Stock?

2026-07-09 10:41:32

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

3 Dirt Cheap Healthcare Shares Under $30 to Buy Right Now

2026-07-07 13:19:51

Healthcare has been an unloved corner of the market in 2026, but that neglect has created a rare setup: quality names trading in single-digit and low-double-digit territory while still throwing off cash, growing earnings, and reaffirming guidance.

Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

2026-07-06 13:09:01

Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion.

Viatris (VTRS) is a Great Momentum Stock: Should You Buy?

2026-07-02 13:01:13

Does Viatris (VTRS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026

2026-07-01 06:59:00

PITTSBURGH, July 1, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report second-quarter 2026 financial results on Thursday, August 6, 2026. Company executives will host a conference call and live webcast at 8:30 a.m.

Here's Why Viatris (VTRS) is a Strong Momentum Stock

2026-06-29 10:50:24

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Frequently Asked Questions

What is the current Viatris Inc. (VTRS) stock price?

Viatris Inc.(NASDAQ:VTRS) stock price is $17.59 in the last trading session. During the trading session, VTRS stock reached the peak price of $17.68 while $8.63 was the lowest point it dropped to. The percentage change in VTRS stock occurred in the recent session was 3.53% while the dollar amount for the price change in VTRS stock was $0.6.

VTRS's industry and sector of operation?

The NASDAQ listed VTRS is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.

Who are the executives of VTRS?

Matthew Joseph Maletta | Chief Legal Officer
Andrew Enrietti | Chief Administrative & Transformation Officer
Paul Campbell | Interim CFO, Chief Accounting Officer & Corporate Controller
Corinne Le Goff | Chief Commercial Officer
Peter McCormick | Chief Supply Officer

How many employees does VTRS have?

Number of VTRS employees currently stands at 30000. VTRS operates from 1000 Mylan Boulevard, Canonsburg, PA 15317, US.

Link for VTRS official website?

Official Website of VTRS is: https://www.viatris.com

How do I contact VTRS?

VTRS could be contacted at phone #724 514 1800 and can also be accessed through its website. VTRS operates from 1000 Mylan Boulevard, Canonsburg, PA 15317, US.

How many shares of VTRS are traded daily?

The average number of VTRS shares traded daily for last 3 months was 11.09M.

What is the market cap of VTRS currently?

The market value of VTRS currently stands at $20.48B with its latest stock price at $17.59